The ARTO™ System - Transcatheter Annular Reduction Therapy (TART) - our simple, one size technology to treat functional mitral regurgitation.

Image description

The ARTO™ System, the company's initial platform, targets functional mitral valve regurgitation associated with congestive heart failure through direct shortening of the minor axis of the mitral valve. Its venous based delivery results in a stress-free, simple procedure that won't affect future therapy. Simple venous based delivery provides exceptional control resulting in an easy, reliable, and predictable repair.

"The ARTO System provides an opportunity not previously available to patients of congestive heart failure. The ARTO System is administered in an extremely calm and low-risk procedure to improve heart function
and enhance quality of life."

- Andrejs Erglis, MD, Chief of Latvian Centre of Cardiology
at Paul Stradins Clinical University Hospital

tab photo

Innovative Therapy for CHF-related mitral valve regurgitation

The ARTO System reestablishes normal anatomic relationships of the mitral valve through a unique system designed to enhance heart function.
Learn More

Experienced, dedicated team leads the way

Our collective experience of more than 130 years of medical device innovations is focused on improving the lives of people living with heart failure.
Learn More

Maveric Trial

MAVERIC Trials to demonstrate safety and performance

Our worldwide multi-centre clinical trials are designed to demonstrate that the device can be delivered safely and provide sustained improvement in CHF-related mitral regurgitation.
Learn More

News & Events

EuroPCR 2018
May 22 - May 25, 2018
Learn More

TVT 2018
June 21 - June 23, 2018
Learn More